STP Virtual CE Course: Antibody Drug Conjugates (ADCs) as Cancer Therapies

When:  Sep 11, 2020 from 12:00 PM to 3:30 PM (ET)

Antibody Drug Conjugates (ADCs) as Cancer Therapies

FRIDAY, SEPTEMBER 11

Co-Chairs: William O. Iverson, DVM, Consultant; and Nancy E. Everds, DVM, DACVP, Seattle Genetics

Antibody-drug conjugates (ADCs), which use a specific antibody to deliver a toxic payload to target cells, hold great promise to increase efficacy and reduce adverse side effects, especially for oncology drugs. Six ADC molecules have received marketing approval in the US over the past 18 years. Nonclinical safety assessment has proven challenging as many ADCs still have steep dose-response curves and low therapeutic indices. Toxicities in many different organs and tissues have been seen, including bone marrow, skin, liver, kidney, eye, gastrointestinal tract, and nervous system. ADC-related toxicities may be more challenging to predict and manage than those seen with small molecules or unconjugated antibodies. This has led to more sophisticated engineering of antibodies, linkers, and drugs to increase internalization of drug by target cells, decrease off-target toxicity, and decrease bystander effects. This course will give an overview of synthesis and mechanisms of representative ADCs, and the clinical and anatomic pathology findings associated with different classes of agents, including immunomodulatory molecules and PROTACS.

Immune Modulatory Activity of Traditional and Nontraditional ADCs
Shyra J. Gardai, PhD, Seattle Genetics

Recent Progress in Antibody Drug Conjugates and PROTACs as New Modalities: Application to Oncology Drug Discovery
Lakshmaiah Gingipalli, PhD, AstraZeneca

Clinical Pathology Effects of Antibody Drug Conjugates in Toxicology Studies
Niraj K. Tripathi, BVSc, MVSc, PhD, DACVP, Covance

Anatomic Pathology Associated with Antibody Drug Conjugates
Matthew D. Smith, DVM, PhD, DACVP, Charles River Laboratories

Registration    View Next Course